Free Trial
NASDAQ:TPST

Tempest Therapeutics Q4 2024 Earnings Report

Tempest Therapeutics logo
$6.18 -0.05 (-0.80%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$6.24 +0.06 (+0.97%)
As of 07:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tempest Therapeutics EPS Results

Actual EPS
-$4.03
Consensus EPS
-$3.12
Beat/Miss
Missed by -$0.91
One Year Ago EPS
N/A

Tempest Therapeutics Revenue Results

Actual Revenue
$0.49 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tempest Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 27, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Tempest Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tempest Therapeutics Earnings Headlines

Q2 EPS Estimate for Tempest Therapeutics Raised by Analyst
Man who predicted $100K Bitcoin sees a huge run coming for another coin …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.
See More Tempest Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tempest Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tempest Therapeutics and other key companies, straight to your email.

About Tempest Therapeutics

Tempest Therapeutics (NASDAQ:TPST), a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

View Tempest Therapeutics Profile

More Earnings Resources from MarketBeat